{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:44:37Z","timestamp":1790171077997,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":707,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.exphem.2020.06.005","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T02:48:25Z","timestamp":1593571705000},"page":"33-41.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Characterization of resistance to a recombinant hexameric Fas-ligand (APO010) in human cancer cell lines"],"prefix":"10.1016","volume":"87","author":[{"given":"Haatisha","family":"Jandu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anker","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Stenvang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2020.06.005_bib0001","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.06.005_bib0002","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000\u20132014","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2020.06.005_bib0003","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1200\/JCO.2011.38.0899","article-title":"Cancer immunotherapy comes of age","volume":"29","author":"Topalian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2020.06.005_bib0004","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s40265-014-0305-6","article-title":"Clinical impact of checkpoint inhibitors as novel cancer therapies","volume":"74","author":"Shih","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.exphem.2020.06.005_bib0005","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/leu.2015.104","article-title":"The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study","volume":"29","author":"Suen","year":"2015","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.exphem.2020.06.005_bib0006","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase 1b study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2020.06.005_bib0007","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.169.5.1747","article-title":"A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor","volume":"169","author":"Yonehara","year":"1989","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2020.06.005_bib0008","doi-asserted-by":"crossref","first-page":"7795","DOI":"10.1074\/jbc.270.14.7795","article-title":"A novel protein that interacts with the death domain of Fas\/APO1 contains a sequence motif related to the death domain","volume":"270","author":"Boldin","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2020.06.005_bib0009","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/cdd.2015.3","article-title":"The role of CD95 and CD95 ligand in cancer","volume":"22","author":"Peter","year":"2015","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.exphem.2020.06.005_bib0010","first-page":"109","article-title":"Fas ligand based immunotherapy: a potent and effective neoadjuvant with checkpoint inhibitor properties, or a systemically toxic promoter of tumor growth","volume":"21","author":"Modiano","year":"2016","journal-title":"Discov Med"},{"key":"10.1016\/j.exphem.2020.06.005_bib0011","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1128\/MCB.23.4.1428-1440.2003","article-title":"Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex","volume":"23","author":"Holler","year":"2003","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.exphem.2020.06.005_bib0012","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.leukres.2005.08.006","article-title":"A Fas agonist induces high levels of apoptosis in haematological malignancies","volume":"30","author":"Greaney","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2020.06.005_bib0013","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/10428199609054860","article-title":"Fas antigen\/APO-1 (CD95) expression on myeloma cells","volume":"23","author":"Shima","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2020.06.005_bib0014","unstructured":"A phase i dose finding study of APO010 in patients with solid tumors. ClinicalTrials.gov identification: NCT00437736."},{"key":"10.1016\/j.exphem.2020.06.005_bib0015","unstructured":"Safety and pharmacokinetics of rising doses of APO010 in relapsed\/refractory multiple myeloma patients selected by DRP. ClinicalTrials.gov identification: NCT03196947."},{"key":"10.1016\/j.exphem.2020.06.005_bib0016","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1021\/pr400457u","article-title":"TIMP-1 increases expression and phosphorylation of proteins associated with drug resistance in breast cancer cells","volume":"12","author":"Hekmat","year":"2003","journal-title":"J Proteome Res"},{"key":"10.1016\/j.exphem.2020.06.005_bib0017","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0014-5793(98)00855-2","article-title":"CD95-mediated apoptosis: no variation in cellular sensitivity during cell cycle progression","volume":"432","author":"Hueber","year":"1998","journal-title":"FEBS Lett"},{"key":"10.1016\/j.exphem.2020.06.005_bib0018","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1126\/science.7533326","article-title":"The Fas death factor","volume":"267","author":"Nagata","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.exphem.2020.06.005_bib0019","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.bbcan.2006.07.002","article-title":"Does CD95 have tumor promoting activities?","volume":"1775","author":"Peter","year":"2005","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.exphem.2020.06.005_bib0020","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1038\/sj.onc.1207558","article-title":"Death receptors in chemotherapy and cancer","volume":"23","author":"Debatin","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2020.06.005_bib0021","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1186\/bcr456","article-title":"Tumour Fas ligand: Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer","volume":"4","author":"Reimer","year":"2002","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.exphem.2020.06.005_bib0022","doi-asserted-by":"crossref","first-page":"15610","DOI":"10.18632\/oncotarget.14779","article-title":"Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer","volume":"8","author":"Blok","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2020.06.005_bib0023","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1172\/JCI117462","article-title":"Anti-Fas\/APO-1 antibody-mediated apoptosis of cultured human glioma cells: induction and modulation of sensitivity by cytokines","volume":"94","author":"Weller","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2020.06.005_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molcel.2005.05.026","article-title":"Regulation of apoptosis by alternative pre-mRNA splicing","volume":"19","author":"Schwerk","year":"2005","journal-title":"Mol Cell"},{"key":"10.1016\/j.exphem.2020.06.005_bib0025","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/cancers10110458","article-title":"Aberrant RNA splicing in cancer and drug resistance","volume":"10","author":"Wang","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.exphem.2020.06.005_bib0026","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1172\/JCI1692","article-title":"Lack of cell surface Fas\/APO-1 expression in pulmonary adenocarcinomas","volume":"101","author":"Nambu","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2020.06.005_bib0027","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/neuonc\/noq176","article-title":"APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo","volume":"13","author":"Eisele","year":"2011","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.exphem.2020.06.005_bib0028","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/sj.leu.2400827","article-title":"Deficient activation of the CD95 (APO-1\/Fas) system in drug-resistant cells","volume":"11","author":"Friesen","year":"1997","journal-title":"Leukemia"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X20302642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X20302642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:35:00Z","timestamp":1759566900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X20302642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":28,"alternative-id":["S0301472X20302642"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2020.06.005","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of resistance to a recombinant hexameric Fas-ligand (APO010) in human cancer cell lines","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2020.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}